Protagonist Therapeutics Begins Phase 2b Trial of PTG-100 as Ulcerative Colitis Treatment

Protagonist Therapeutics Begins Phase 2b Trial of PTG-100 as Ulcerative Colitis Treatment
Protagonist Therapeutics has started a Phase 2b clinical trial to evaluate PTG-100, its lead candidate as a potential treatment for ulcerative colitis (UC). The multicenter, randomized, double-blind, placebo-controlled, parallel, adaptive two-stage trial (NCT02895100) will assess the effectiveness, safety and tolerability of PTG-100 in about 240 adults with moderate to severe UC. Researchers will randomly assign patients to one of three doses of PTG-100 -- 150, 300, or 900 mg -- or to a placebo. Patients will receive doses once a day orally for 12 weeks, followed by four weeks of safety assessment. PTG-
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *